Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from 89bio ( (ETNB) ) is now available.
On September 17, 2025, 89bio announced a merger agreement to be acquired by Roche for $14.50 per share in cash, with the potential for additional payments based on milestone achievements, totaling up to $20.50 per share. This acquisition, valued at approximately $3.5 billion, reflects pegozafermin’s potential in treating MASH and is expected to close in the fourth quarter of 2025, pending regulatory approvals and other conditions.
The most recent analyst rating on (ETNB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on 89bio stock, see the ETNB Stock Forecast page.
Spark’s Take on ETNB Stock
According to Spark, TipRanks’ AI Analyst, ETNB is a Neutral.
The overall score for 89bio is primarily weighed down by the financial performance due to ongoing losses and cash flow issues. Technical indicators show bearish momentum, adding to the risk. Although corporate events highlight promising clinical progress, the company’s valuation remains low due to negative earnings, typical in the biotech industry. The stock reflects high-risk, high-reward potential.
To see Spark’s full report on ETNB stock, click here.
More about 89bio
89bio is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardiometabolic diseases. The company is advancing its lead candidate, pegozafermin, for treating metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
Average Trading Volume: 1,483,266
Technical Sentiment Signal: Sell
Current Market Cap: $1.2B
For an in-depth examination of ETNB stock, go to TipRanks’ Overview page.